Skip to main content
TipRanks
Go Ultimate75% OFF

Joseph Araujo Insider Profile

4 Followers

Joseph Araujo, former Chief Science Officer at Mindset Pharma Inc., holds 64.00K shares in Mindset Pharma Inc. (Ticker: TSE:MSET). Most recently, Joseph Araujo Bought 20,000 shares of Mindset Pharma Inc. on Jan 25, 2022 for an estimated value of C$10.40K.

Joseph Araujo's Trading History

MSET
Mindset Pharma Inc.
Jan 25, 2022―Informative Buy10.40KC$47.36K
TSE:MSET
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
Jan 25, 2022Informative BuyC$10.40K20,000C$0.52-53.20%―
Jan 22, 2022Informative BuyC$10.50K15,000C$0.70-48.30%―
Jan 21, 2022Informative BuyC$10.65K15,000C$0.71-48.30%―
Apr 20, 2021Informative BuyC$6.51K14,000C$0.46+1.90%―

You May Also Like

Joseph Araujo insider profile FAQ

What is the percentage of profitable transactions made by Joseph Araujo?
The percentage of profitable transactions made by Joseph Araujo is 25%.
What is the average return per transaction made by Joseph Araujo?
The average return per transaction made by Joseph Araujo is -36.90%.
What stocks does Joseph Araujo hold?
Joseph Araujo holds: TSE:MSET stocks.
What was Joseph Araujo’s latest transaction?
Joseph Araujo’s latest transaction was an Informative Buy of C$10.40K.
What was Joseph Araujo's most profitable transaction?
Joseph Araujo’s most profitable transaction was an Informative Buy of TSE:MSET stock on April 20, 2021. The return on the trade was 1.90%.
What is Joseph Araujo's role in Mindset Pharma Inc.?
Joseph Araujo's role in Mindset Pharma Inc. is Chief Science Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.